Prevnar 20 (pneumococcal 20-valent conjugate vaccine) / Pfizer - LARVOL DELTA

A Study to Learn How Effective is PCV20 to Help Stop Adults Who Have a Higher Chance of Getting Pneumonia (clinicaltrials.gov) - P=N/A | N=846279 | Not yet recruiting | Sponsor: Pfizer

New trial • Infectious Disease • Pneumococcal Infections • Pneumonia • Respiratory Diseases

Study of a Single Dose of a 21-valent Pneumococcal Conjugate Vaccine in Children and Adolescents With Sickle Cell Disease (clinicaltrials.gov) - P3 | N=100 | Not yet recruiting | Sponsor: Sanofi

New P3 trial • Genetic Disorders • Hematological Disorders • Infectious Disease • Pneumococcal Infections • Sickle Cell Disease

A Study to Understand the Safety of the 20vPnC Vaccine in Healthy Chinese Adults, Children, and Infant (clinicaltrials.gov) - P1 | N=200 | Recruiting | Sponsor: Pfizer | N=100 ➔ 200

Enrollment change • Infectious Disease • Pneumococcal Infections

A Study to Learn About How Well the Prevnar 20 Vaccine Works for Pneumonia in People Who Are 65 Years and Older (clinicaltrials.gov) - P=N/A | N=22234435 | Active, not recruiting | Sponsor: Pfizer | Trial completion date: Sep 2025 ➔ Jun 2026 | Trial primary completion date: Sep 2025 ➔ Jun 2026

Real-world evidence • Trial completion date • Trial primary completion date • Infectious Disease • Pneumococcal Infections • Pneumonia • Respiratory Diseases

A Study to Learn About How Safe and Effective is 20vPnC and 13vPnC Vaccines in Chinese Adults (clinicaltrials.gov) - P1 | N=400 | Active, not recruiting | Sponsor: Pfizer | N=158 ➔ 400

Enrollment change • Infectious Disease • Pneumococcal Infections

Evaluating the implementation of the 20-valent pneumococcal conjugate vaccine for paediatric immunization in Australia. (PubMed, Vaccine) - "This cost-effectiveness analysis estimated that adoption of PCV20 into the Australian paediatric NIP would be dominant versus PCV13 and PCV15, leading to health benefits and cost-savings."

Journal • Infectious Disease • Otorhinolaryngology • Pediatrics • Pneumococcal Infections • Pneumonia • Respiratory Diseases

Cost-Effectiveness of 20-Valent Pneumococcal Conjugate Vaccine (PCV20) Among High-Risk Adults in Taiwan (ISPOR-EU 2025) - "CEA suggests use of PCV20—in lieu of current Taiwan CDC recommendations for pneumococcal vaccination in high-risk adults aged 18-64 years and all adults aged ≥65 years—would be cost saving and represent an efficient use of healthcare resources and would substantially reduce the numbers of cases and deaths due to pneumococcal disease."

Clinical • Cost effectiveness • HEOR • Infectious Disease • Pneumococcal Infections • Pneumonia • Respiratory Diseases

A Comparison of the Potential Public Health Impact of PCV15 and PCV20 in French Infants (ISPOR-EU 2025) - "Vaccine effectiveness (VE) was extrapolated from PCV13 effectiveness and PCV7 efficacy studies... PCV20 vaccination is projected to provide greater protection against pneumococcal disease in French infants than PCV15, regardless of VE assumptions or dosing schedules. These results support the preferential use of PCV20 to maximize disease prevention in the first year of life."

Infectious Disease • Otorhinolaryngology • Pneumococcal Infections • Pneumonia • Respiratory Diseases

Prophylaxis and Vaccinations for Infections with BCMA Chimeric Antigen Receptor T-Cell Therapy in Multiple Myeloma: Usmirc Practice Patterns (ASH 2024) - "All 8 centers offered ide-cel while cilta-cel was offered by 6...Other vaccines were given less frequently with Prevnar 20 at 64.3%, Pentavalent (DPT, Hep B, H. influenzae) at 57%, Hep B virus (HBV), RZV, and MCV4 each at 50%. Pneumovax 23 and MMR (live) were recommended by 42.8%, HPV by 35.7%, and VZV (live) by 21.4%...While there are limitations in the generalizability of these practices, these findings demonstrate marked differences in clinical practices across USMIRC centers. Further studies are needed to correlate these practices with downstream infection rates and to allow the development of consensus guidelines for both higher and lower-volume centers."

CAR T-Cell Therapy • Cytomegalovirus Infection • Hematological Disorders • Hematological Malignancies • Hepatitis B • Infectious Disease • Influenza • Multiple Myeloma • Neutropenia • Oncology • Pneumonia • Respiratory Diseases • CD4

A Cost-Effectiveness Analysis of the Switch to 20-Valent Pneumococcal Conjugate Vaccine From Lower-Valent Vaccines in the French Pediatric Population (ISPOR-EU 2025) - "This study predicted that infant immunization with PCV20 was the most cost-effective option compared with PCV13 and PCV15. These results could help decision-makers implement the optimal PCV strategy in the French pediatric NIP."

Clinical • Cost effectiveness • HEOR • Infectious Disease • Otorhinolaryngology • Pediatrics • Pneumococcal Infections • Pneumonia • Respiratory Diseases

Invasive Pneumococcal Disease at Eight Children's Hospitals in the United States, 2018-2023. (PubMed, Pediatr Infect Dis J) - "PCV13 serotypes (especially 3, 19A and 19F) continue to account for 30% of IPD in US children 8-13 years after PCV13 was introduced. Vancomycin should still be included in empiric treatment of bacterial meningitis in children. The introduction of PCV20 for routine administration to infants could result in further reductions in IPD in children."

Journal • CNS Disorders • Infectious Disease • Pneumococcal Infections

Cost-Effectiveness Assessment of 20-Valent Pneumococcal Conjugate Vaccine (PCV20) Among At-Risk and High-Risk Adults in India (ISPOR-EU 2025) - "Compared to PCV13 ◊PPV23, PCV20 in at-/high-risk older adults would be cost-saving and cost-effective from both private and government payer perspectives. Furthermore, from private payer perspective, PCV20 would be cost-effective compared with all other vaccination strategies considered."

Clinical • Cost effectiveness • HEOR • Infectious Disease • Pneumococcal Infections • Pneumonia • Respiratory Diseases

Cost-Effectiveness Analysis of the 13-Valent Pneumococcal Conjugate Vaccine Compared With Higher-Valent Alternatives in the Pediatric Population of Paraguay (ISPOR-EU 2025) - "Direct and indirect VE was derived from PCV7 and PCV13 clinical efficacy, effectiveness, and impact studies... PCV20 offers broader serotype coverage and was estimated to avert more PD cases and deaths than PCV13 and PCV15. Replacing lower-valent PCVs with PCV20 in the NIP was the most cost-saving and effective (dominant) option in Paraguay."

Clinical • Cost effectiveness • HEOR • Infectious Disease • Otorhinolaryngology • Pediatrics • Pneumococcal Infections • Pneumonia • Respiratory Diseases

Prophylaxis and Vaccinations for Infections with BCMA and GPRC5D T-Cell Engagers in Multiple Myeloma: Usmirc Practice Patterns (ASH 2024) - "All centers offered both teclistamab and talquetamab, and 7 also used elranatamab...Other vaccines were used less frequently : Prevnar 20 (33%), Pentavalent (DPT, Hep B, H.influenzae) (27%), Hep B virus (27%), RZV (27%), MCV4 (20%), Pneumovax 23 (20%), HPV (20%), MMR live (20%) and VZV live (6%)...While there are limitations in the generalizability of these practices, these findings demonstrate several areas with varying clinical practices across USMIRC centers. Further studies are needed to correlate these practices with infection rates and to allow development of consensus guidelines for both academic and community centers."

Cytomegalovirus Infection • Hematological Disorders • Hematological Malignancies • Hepatitis B • Infectious Disease • Influenza • Multiple Myeloma • Neutropenia • Oncology • Pneumonia • Respiratory Diseases • Respiratory Syncytial Virus Infections • CD4

Public Health Impact of 25 Years of Pneumococcal Conjugate Vaccination in Children 5 Years Old: A Modeling Analysis (ISPOR-EU 2025) - "The vaccination of over 500 million infants with PCV7, PCV13, and PCV20 has substantially reduced the global burden of pneumococcal disease, preventing over 250 million cases and more than 1 million deaths over 25 years. Despite these achievements, pneumococcal disease remains a concern. Expanding PCV programs worldwide and implementing higher-valent PCVs in pediatric immunization programs could lead to greater reductions in disease burden."

Clinical • Infectious Disease • Pediatrics • Pneumococcal Infections

Healthcare providers' preferences for pediatric pneumococcal vaccination recommendations in the United States. (PubMed, Expert Rev Vaccines) - "93% of HCPs preferred PCV20 over PCV15 for children aged ≤18 years. HCPs' choices indicated a preference for the use of PCV20 in both a clinical setting and in pediatric pneumococcal vaccination recommendations, due to the higher number of serotypes covered by PCV20."

Journal • Infectious Disease • Pediatrics • Pneumococcal Infections

Cost-Effectiveness Analysis of Pediatric and Adult Pneumococcal Conjugate Vaccine Strategies in Canada (ISPOR-EU 2025) - "OBJECTIVES: In Canada, PCV15 (Vaxneuvance) and PCV20 (Prevnar 20) are approved for use in adult and pediatric populations... Funding PCV20 for both pediatric and adult public immunization programs could result in greater health and economic gains than funding PCV15 in pediatric and PCV21 in adult programs. Additionally, using one vaccine for all ages could enhance equity, simplify vaccine procurement, and improve logistical inefficiencies related to training, supply, and storage."

Clinical • Cost effectiveness • HEOR • Infectious Disease • Otorhinolaryngology • Pediatrics • Pneumococcal Infections • Pneumonia • Respiratory Diseases

Cost-Effectiveness Analysis Of The 13-Valent And 20-Valent Pneumococcal Conjugate Vaccine In The Kazakh Adult Population (ISPOR-EU 2025) - "Vaccinating with a single dose of PCV13 or PCV20 in targeted adult population in Kazakhstan is expected to significantly reduce clinical and economic burdens associated with PD."

Clinical • Cost effectiveness • HEOR • Infectious Disease • Pneumococcal Infections

Immunogenicity and safety of concomitant vaccines given with 20-valent pneumococcal conjugate vaccine in healthy infants. (PubMed, Vaccine) - P3 | "Immune responses to routine pediatric vaccines given with PCV20 were noninferior to those when given with PCV13. PCV20 may be safely administered with other routine pediatric vaccines. (NCT04382326; NCT04546425)."

Journal • Hepatitis B • Infectious Disease • Inflammation • Influenza • Measles • Mumps • Pediatrics • Pertussis • Pneumococcal Infections • Respiratory Diseases • Rubella • Tetanus • Varicella Zoster

Impact of Higher-Valent Pediatric Pneumococcal Vaccines on Hospitalization Burden in Norway (ISPOR-EU 2025) - "The model used PCV13 clinical effectiveness and impact studies as well as PCV7 efficacy studies for higher-valent vaccine direct and indirect effect estimates... Replacing PCV13 with PCV20 in Norway's Childhood Immunisation Programme could significantly reduce hospital burden compared to replacing PCV13 with PCV15. These findings support the inclusion of PCV20 in national immunization schedules to reduce pneumococcal disease burden and associated hospital strain."

Clinical • Pneumococcal vaccines • Infectious Disease • Pediatrics • Pneumococcal Infections • Pneumonia • Respiratory Diseases

Impact of Real-World Effectiveness vs. Previous Assumptions on Estimates of Economic and Clinical Benefit of 20-Valent Pneumococcal Conjugate Vaccine in Adults Across Countries (ISPOR-EU 2025) - "Using PCV20 VE derived from real-world evidence predicts greater economic and clinical benefits compared to previous VE estimates used in economic models, suggesting existing economic models evaluating PCV20 in adults are likely conservative. Vaccine policy makers should incorporate available real-world effectiveness data when considering higher-valent PCVs for adults."

Clinical • Real-world • Real-world effectiveness • Real-world evidence • Infectious Disease • Pneumococcal Infections • Pneumonia • Respiratory Diseases

Impact of Higher-Valent Pediatric Pneumococcal Vaccines on Antimicrobial Resistant Infections and Antibiotic Prescriptions in Greece (ISPOR-EU 2025) - "Widespread pediatric use of PCV20 in Greece can reduce AMR and antibiotic consumption. PCV20 implementation has the potential to substantially enhance public health in Greece while also helping to address the growing global challenge of AMR."

Clinical • Pneumococcal vaccines • Infectious Disease • Otorhinolaryngology • Pediatrics • Pneumococcal Infections • Pneumonia • Respiratory Diseases

Conceptual Methodological Framework for Incorporating Antimicrobial Resistance Considerations in Economic Models for Pneumococcal Conjugate Vaccines. (PubMed, Infect Dis Ther) - "A simplified model can effectively incorporate critical AMR parameters for a more comprehensive evaluation of PCVs. Our framework also identifies key data gaps that should be addressed for future modeling efforts."

Journal • Infectious Disease • Pneumococcal Infections

Improving Vaccination Rates in the Rheumatology Clinic (ACR Convergence 2025) - "Post-intervention vaccination rates were assessed from November 1, 2024, to March 31, 2025 (Period 2). Baseline data collected from period 1 revealed administration of 69 influenza vaccines and 2 Pneumococcal (Prevnar 20) vaccines... Vaccinations are crucial in patients with rheumatic and musculoskeletal diseases and receiving immunosuppressive therapy. Baseline data revealed low influenza and pneumococcal vaccine rates, highlighting a critical gap in preventative care. After implementing patient questionnaires and staff education, we observed a marked increase in vaccine uptake—suggesting that targeted interventions with a multidisciplinary team of physicians and ancillary medical staff can effectively improve vaccination rates in high-risk populations."

Infectious Disease • Influenza • Musculoskeletal Diseases • Pneumococcal Infections • Preventive care • Respiratory Diseases • Rheumatology

A Phase 2 Study to Evaluate the Safety, Tolerability, and Immune Response of AFX3772 Vaccine in Healthy Infants (clinicaltrials.gov) - P2 | N=388 | Completed | Sponsor: GlaxoSmithKline | Active, not recruiting ➔ Completed | Trial completion date: Jul 2026 ➔ Sep 2025 | Trial primary completion date: Jul 2026 ➔ Sep 2025

Trial completion • Trial completion date • Trial primary completion date • Infectious Disease • Pneumococcal Infections • Pneumonia • Respiratory Diseases